Skip to Main Content
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Francine Foss, MD

Professor of Medicine (Hematology) and of Dermatology; Director, Multidisciplinary T cell Lymphoma Program, Hematology; Scientific Leader, Lymphoma DART, Yale Cancer Center; Host, Yale Cancer Center Answers, Yale Cancer Center

Contact Information

Francine Foss, MD
Download CV

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Extensive Research Description

Over the last 10 years I have been a leader in the establishment of an international T cell lymphoma working group. I initiated a T Cell Lymphoma workshop at the International Conference on Malignant Lymphoma 12 years ago and from that workshop, the United States Peripheral T cell Lymphoma group was formed. I subsequently initiated the first T Cell Lymphoma Forum, an international meeting incorporating basic and clinical sciences related to T cell lymphomas. (www.tcellforum.com). This meeting is now recognized as the pre-eminent international T cell Lymphoma meeting. A number of collaborations have arisen from these meetings and there is now a world-wide effort to coordinate the care of patients with T cell lymphomas.

Another initiative that I undertook was to establish a T Cell Lymphoma Registry. I initiated and am the Principal Investigator for the COMPLETE T cell Registry (www. Clinical trials.gov/COMPLETE REGISTRY). This is a US based registry to determine the frequency of types of T cell lymphoma, physician’s treatment patterns, outcomes with therapy, and prognostic factors associated with common and rare subtypes. Thus far this registry has enrolled 500 patients in its first phase, and the second phase of enrollment is about to begin. I have also been a co-Founder of a European based registry, the TCELL PROJECT (www.TCELLPROJECT.org). This registry is similar to COMPLETE but includes pathologic review and includes many other countries in Asia, South America, and Europe as well as in the US. This registry has enrolled 1000 patients and is ongoing. In a recent initiative, I have collaborated with several countries in Latin American to initiate their own registry which will interface with our existing registries.

I was one of the founders of the United States Cutaneous Lymphoma Consortium. This organization includes oncologists, dermatologists, radiation oncologists, and pathologists and its goal is to develop novel clinical trials and to define clinical approaches for patients with cutaneous lymphomas. I also serve as a Co-Chair of the Registry Committee and have been instrumental in starting a patient registry for both T and B cell cutaneous lymphoma patients. This registry has a research focus. I am now the President of the USCLC.

Coauthors

Research Interests

Biological Factors; Graft vs Host Disease; Hodgkin Disease; Immune System Diseases; Leukemia, Hairy Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Sezary Syndrome; Skin Neoplasms; Leukemia, B-Cell; Leukemia, T-Cell; Leukemia, Prolymphocytic, T-Cell; Leukemia, Prolymphocytic, B-Cell; Composite Lymphoma; Chemicals and Drugs

Public Health Interests

Immunology

Selected Publications

Clinical Trials

ConditionsStudy Title
LungAn Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer
Leukemia, otherA Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Lymphoid LeukemiaA Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Anus; Breast - Female; Breast - Male; Colon; Corpus Uteri; Esophagus; Hodgkin's Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Phase I; Unknown Sites; Breast; Cervix; Urinary BladderPhase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Hodgkin's Lymphoma; Leukemia, not otherwise specified; Leukemia, other; Lymphoid Leukemia; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Hematopoietic; Supportive CarePhase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
Non-Hodgkin's LymphomaA Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
Leukemia, not otherwise specified; Leukemia, other; Multiple Myeloma; Non-Hodgkin's LymphomaA Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma
Edit Profile